Novelion Therapeutics Observes World Lipodystrophy Day
31 mars 2017 06h00 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, March 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for...
Novelion Therapeutics’ Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society
30 mars 2017 16h15 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new...
Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results
15 mars 2017 07h00 HE
|
Novelion Therapeutics, Inc.
Company Reiterates FY 2017 Total Net Product Sales Expected to be Between $155 and $165 million Global Expansion Plans for Metreleptin Opportunity Underway VANCOUVER, British Columbia,...
Novelion Therapeutics to Announce Preliminary Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017
13 mars 2017 16h15 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, March 13, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for...
Novelion Therapeutics Announces Presentation at the 29th Annual ROTH Conference
08 mars 2017 16h05 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 08, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new...
U.S. Patent Trial and Appeal Board Affirms Lomitapide Patents with Favorable IPR Decisions
07 mars 2017 08h43 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia & CAMBRIDGE, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new...
Novelion Therapeutics Announces Presentation at the Cowen and Company 37th Annual Health Care Conference
01 mars 2017 16h05 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new...
Novelion Therapeutics Observes Rare Disease Day
28 févr. 2017 08h05 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new...
Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency
23 janv. 2017 08h45 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for...
Novelion Therapeutics Reports Preliminary 2016 Net Product Sales and Provides 2017 Outlook
09 janv. 2017 07h40 HE
|
Novelion Therapeutics, Inc.
- Company Reports Preliminary Total Net Product Sales Expected to be Between $150 million and $152 million, Exceeding High End of Prior Guidance - Global Expansion Plans for Metreleptin...